Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs VOSOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
90–95%, primarily to albumin.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Otic: 80–90% (local absorption with minimal systemic).
No dose adjustment required. Topical use with minimal systemic absorption.
No dosage adjustment required for renal impairment.
No dose adjustment required. Topical use with minimal systemic absorption.
No dosage adjustment required for hepatic impairment.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
No FDA black box warning.
None
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
No known food interactions with topical Aclovate.
No known food interactions. Alcohol consumption is not restricted.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs VOSOL HC, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.